domenica, 3 maggio 2026

Notizie AIOM – anno XV

Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

Talazoparib inhibits poly(ADP-ribose) polymerase (PARP) catalytic activity, trapping PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We evaluated talazoparib therapy in this 2-part, phase I, first-in-human trial. Antitumor activity, maximum tolerated ...
Leggi tutto

ASCO Endorses ACS Head and Neck Cancer Survivorship Care Guideline

March 8, 2017 - As reported in the Journal of Clinical Oncology by Larissa Nekhlyudov, MD, MPH, of Brigham & Women’s Hospital, Harvard Medical School, and colleagues, ASCO has endorsed the 2016 American Cancer Society (ACS) guideline on head and neck cancer survivorship ...
Leggi tutto

FDA Lifts Clinical Hold on Vadastuximab Talirine Trials in AML

March 6, 2017 - The FDA has lifted its clinical hold on several phase I trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML), according to Seattle Genetics, the manufacturer of the antibody-drug conjugate. In late December 2016, the FDA enacted the ...
Leggi tutto

FDA Review Continues for Pembrolizumab in MSI-H Cancer

March 10, 2017 - A supplemental biologics license application (sBLA) for pembrolizumab for previously treated patients with advanced microsatellite instability-high (MSI-H) cancer remains under review by the FDA, according to a statement from Merck, the manufacturer of the ...
Leggi tutto

Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?

To explore the impact of primary debulking surgery (PDS) to minimal but gross residual disease (RD) in women with bulky stage IIIC ovarian, fallopian tube, or primary peritoneal cancer. We retrospectively reviewed all patients with the aforementioned diagnosis who underwent ...
Leggi tutto

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to second-line treatment are uncommon. We assessed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety ...
Leggi tutto

Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities

Annual computed tomography (CT) scans are a component of the current standard of care for the posttreatment surveillance of survivors of colorectal cancer (CRC) after curative-intent resection. The authors conducted a retrospective study with the primary aim of assessing ...
Leggi tutto

Precision medicine needs randomized clinical trials

The advent of precision medicine has prompted profound changes in clinical cancer research, and the rising numbers of new therapeutic agents pose challenges in terms of the most appropriate trial designs and effects on the drug-approval process. In the past 5 years, some ...
Leggi tutto

6 marzo 2017 – Lorenzin, Vincelli, Melazzini a insediamento Nucleo NAS in AIFA

6 marzo 2017 – Pubblicazione schede di monitoraggio Registro Obinutuzumab